Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

149/433 Matches for
“Surrogate markers”

“Surrogate markers” Clear all
  1. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009 Match 100

    FibroTest Alcohol HBV HCV +1

  2. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

    Poynard T et al. · Hepatology · 2003 Match 100

    …The aim was to validate their usefulness as surrogate markers of histologic…

    ActiTest FibroTest HCV

  3. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 100

    ### Aims To evaluate the application of the recently proposed recommendations by the…

    FibroTest NashTest Metabolic

  4. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

    Coco B et al. · J Viral Hepat · 2007 Match 99

    …FibroScan performed better than the other surrogate markers of fibrosis (P < 0…

    FibroTest Alcohol HBV HCV +1

  5. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 99

    …and the SteatoTest, a biochemical surrogate marker of liver steatosis. The FLI…

    SteatoTest Metabolic

  6. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.

    Alric L et al. · Transpl Int · 2009 Match 99

    To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…

    FibroTest HBV HCV

  7. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 98

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  8. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 98

    …Among the noninvasive surrogate markers and techniques used to detect liver fibrosis…

    FibroTest Alcohol

  9. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 98

    surrogate for steatosis >5%), IR (HOMA-IR>2.7 as a surrogate

    FibroTest SteatoTest HBV HCV +1

  10. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.

    Poynard T et al. · J Viral Hepat · 2002 Match 97

    …A fibrosis index combining five biochemical markers (alpha2-macroglobulin, haptoglobin, apolipoprotein A1…

    FibroTest HCV

  11. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 97

    ### Background And Aims Diagnostic values of FibroTest (FT) for hepatic fibrosis have…

    FibroTest HBV

  12. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 97

    …ActiTest (FT-AT) as noninvasive markers of histological changes in patients with…

    ActiTest FibroTest HBV

  13. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 96

    ActiTest FibroTest Alcohol HBV +3

  14. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 96

    …HD-UDCA also significantly improved markers of glycemic control and insulin resistance…

    FibroTest Metabolic

  15. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Match 96

    …However, not all correlations observed between noninvasive markers and fibrosis stage at…

    FibroTest HCV

  16. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.

    Le Calvez S et al. · Hepatology · 2004 Match 95

    FibroTest HCV

  17. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 95

    ### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…

    ActiTest FibroTest HCV

  18. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 95

    …Biochemical markers seem particularly useful as a noninvasive alternative to liver biopsy…

    FibroTest HCV

  19. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 94

    FibroTest SteatoTest Metabolic

  20. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.

    Park MS et al. · PLoS One · 2013 Match 94

    ### Background And Aims The FibroTest (FT) demonstrated excellent diagnostic performance in the…

    FibroTest HBV

  21. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?

    Gentile I et al. · Infez Med · 2014 Match 94

    It is estimated that hepatitis C virus (HCV) infects chronically about 160…

    FibroTest HCV

  22. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.

    Elalfy MS et al. · Ann Hepatol · 2013 Match 93

    ### Background The main causes of liver fibrosis in transfusion-dependent thalassemia major…

    ActiTest FibroTest HCV

  23. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

    Castéra L et al. · Gastroenterology · 2005 Match 93

    …combined with currently available biochemical markers (Fibrotest; Biopredictive; and the aspartate transaminase…

    FibroTest HCV

  24. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 93

    …LSM and liver fibrosis biochemical markers were performed on 225 consecutive HBV…

    FibroTest HBV

  25. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 92

    ### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…

    FibroTest HBV

  26. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 92

    ### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…

    FibroTest Alcohol HBV HCV +1

  27. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 92

    FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…

    FibroTest Alcohol HBV HCV +2

  28. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 91

    ### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…

    FibroTest HCV

  29. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 91

    …using transient elastography, and serum markers, ranging from routine laboratory tests to…

    FibroTest HBV HCV HIV

  30. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 91

    ### Background/Aims The aim was to identify a panel of biomarkers (AshTest…

    AshTest Alcohol

  31. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 90

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  32. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.

    Varaut A et al. · Transplantation · 2005 Match 90

    ### Background An accurate diagnosis of hepatitis C virus (HCV)-related liver lesions…

    FibroTest HCV

  33. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 90

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest COVID

  34. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014 Match 89

    Liver biopsy, which was traditionally considered to be the gold standard for…

    FibroTest HBV HCV

  35. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 89

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  36. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 89

    FibroTest Alcohol HBV HCV +3

  37. Noninvasive prediction of fibrosis in patients with chronic hepatitis C.

    Thabut D et al. · Hepatology · 2003 Match 88

    FibroTest HCV

  38. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 88

    …transient elastography (FibroScan) and biochemical markers (Hepascore, Aspartate Transaminase (AST) to platelet…

    FibroTest

  39. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 88

    Liver biopsy, due to its limitations and risks, is an imperfect gold…

    ActiTest FibroTest SteatoTest Alcohol +5

  40. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 87

    FibroTest Metabolic

  41. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.

    Lewin M et al. · Hepatology · 2007 Match 87

    ### Unlabelled Liver biopsy is the gold standard for assessing fibrosis but has…

    FibroTest HCV

  42. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010 Match 87

    ### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…

    ActiTest HCV

  43. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 86

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  44. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

    Patel K et al. · J Viral Hepat · 2009 Match 86

    Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…

    FibroTest HCV

  45. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Match 86

    FibroTest HCV

  46. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 85

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  47. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 85

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  48. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 85

    …Predictive values of blood markers [FibroSURE, aspartate aminotransferase-to-platelet-ratio index…

    FibroTest

  49. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 84

    …We examined year wise results of these markers based on their sensitivity…

    FibroTest HCV

  50. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 84

    …and transient elastography (TE) as markers of occurrence of cirrhosis without complications…

    ActiTest FibroTest HBV

  51. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

    Poynard T et al. · J Hepatol · 2013 Match 84

    ### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…

    ActiTest FibroTest HBV

  52. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 83

    A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…

    FibroTest HBV

  53. Diagnostic value of FibroTest with normal serum aminotransferases.

    Poynard T et al. · Hepatology · 2006 Match 83

    FibroTest HCV

  54. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

    Imbert-Bismut F et al. · Clin Chem Lab Med · 2004 Match 83

    Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…

    ActiTest FibroTest HCV

  55. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 82

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  56. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 82

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  57. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 82

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  58. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 81

    ### Background This prospective, monocentric study was designed to assess the efficacy of…

    FibroTest Alcohol HBV HCV +2

  59. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 81

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  60. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 81

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  61. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

    Boyd A et al. · J Int AIDS Soc · 2017 Match 80

    ### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…

    FibroTest HBV HIV

  62. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 80

    Even though alcohol-related liver disease (ALD) is a major cause of…

    FibroTest Alcohol

  63. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 80

    …Of the noninvasive serum markers, the NAFLD fibrosis score is the most…

    ActiTest FibroTest NashTest SteatoTest +1

  64. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 79

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  65. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Match 79

    ### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…

    ActiTest FibroTest Alcohol HBV +1

  66. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

    Poynard T et al. · Am J Gastroenterol · 2005 Match 79

    ### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…

    ActiTest FibroTest HBV

  67. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 78

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  68. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 78

    …significantly higher than the standard markers: gamma-glutamyl-transpeptidase or alanine aminotransferase…

    SteatoTest Alcohol HBV HCV +1

  69. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

    Myers RP et al. · AIDS · 2003 Match 78

    …non-invasive index of biochemical markers for the prediction of fibrosis in…

    FibroTest HCV HIV

  70. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 77

    ### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…

    FibroTest HCV

  71. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.

    Uyar C et al. · Indian J Pathol Microbiol · 2010 Match 77

    …both determined via serum biochemical markers, were compared with levels of fibrosis…

    ActiTest FibroTest HBV HCV

  72. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 77

    ActiTest AshTest FibroTest NashTest +6

  73. [SWE elastography in assessment of liver fibrosis].

    Zaleska-Dorobisz U et al. · Postepy Hig Med Dosw (Online) · 2015 Match 76

    Liver fibrosis is a relatively common consequence of chronic liver diseases, especially…

    FibroTest HBV HCV

  74. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 76

    …been validated as non-invasive markers of METAVIR fibrosis stages from F0…

    FibroTest HCV

  75. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 76

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  76. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 75

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver…

    FibroTest HCV

  77. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 75

    …combinations of simple serum biochemical markers in patients infected with hepatitis B…

    ActiTest FibroTest Alcohol HBV +2

  78. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Match 75

    ### Aim To assess the usefulness of FibroTest to forecast scores by constructing…

    FibroTest HCV

  79. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 74

    …In a multivariate analysis, factors associated with abnormal markers of liver fibrosis…

    FibroTest Other

  80. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 74

    …AUROC), the best performing serum markers for significant liver fibrosis (METAVIR ≥F2…

    FibroTest HCV

  81. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 74

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  82. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 73

    …However, diagnostic markers for this condition are limited. We hypothesized that specific…

    FibroTest Other

  83. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 73

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  84. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.

    Sebastiani G et al. · J Viral Hepat · 2008 Match 73

    …Few studies investigated noninvasive markers of liver fibrosis in hepatitis C virus…

    FibroTest HCV

  85. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 72

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  86. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 72

    ### Importance The long-term implications of hepatotoxic effects in patients with psoriasis…

    FibroTest NashTest

  87. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009 Match 72

    …not adequately classifiable by noninvasive markers. Hepatitis C virus (HCV) patients (2035…

    FibroTest HCV

  88. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.

    Shaheen AA et al. · HIV Clin Trials · 2008 Match 71

    ### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…

    FibroTest HCV HIV

  89. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.

    de Lédinghen V et al. · J Pediatr Gastroenterol Nutr · 2007 Match 71

    ### Objective Transient elastography (FibroScan) is a novel, noninvasive, rapid bedside method to…

    FibroTest HBV HCV Other

  90. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

    Maor Y et al. · Haemophilia · 2007 Match 71

    Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…

    FibroTest HCV

  91. Changes of non-invasive markers and FibroScan values during HCV treatment.

    Vergniol J et al. · J Viral Hepat · 2009 Match 70

    The recent advent of non-invasive methods for assessment of fibrosis allows…

    FibroTest HCV

  92. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 70

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  93. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Match 70

    ### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…

    FibroTest HCV

  94. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.

    Friedrich-Rust M et al. · J Thorac Cardiovasc Surg · 2008 Match 69

    …to the measured biochemical fibrosis markers. The Spearman correlation coefficient between the…

    ActiTest FibroTest Other

  95. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 69

    ### Aims And Methods Several serum biomarkers such as FibroTest, aspartate transaminase-platelet…

    FibroTest Alcohol HBV HCV +3

  96. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.

    Halfon P et al. · Comp Hepatol · 2002 Match 69

    …Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are an…

    ActiTest FibroTest Alcohol HCV

  97. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.

    Park MS et al. · Liver Int · 2015 Match 68

    ### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…

    FibroTest HBV

  98. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 68

    ### Aim To assess the performance of several non-invasive markers and of…

    FibroTest HBV

  99. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 68

    …The intra-individual variation of biochemical markers was low, and it was…

    ActiTest FibroTest Alcohol HBV +3

  100. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.

    Sène D et al. · Clin Biochem · 2006 Match 67

    ### Objective And Methods We assessed the reliability of non-invasive biological scoring…

    ActiTest FibroTest HCV

  101. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 67

    …the diagnostic use of noninvasive markers of fibrosis in patients with chronic…

    FibroTest Alcohol

  102. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 67

    ### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…

    FibroTest Alcohol HBV HCV +1

  103. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Match 66

    …The aim was to determine the diagnostic utility of noninvasive serum markers

    ActiTest FibroTest HBV

  104. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Match 66

    ### Background Due to common routes of transmission, HIV and HBV are frequently…

    FibroTest HBV HIV

  105. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 66

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  106. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

    d'Arondel C et al. · J Viral Hepat · 2006 Match 65

    …a significant decrease in fibrosis and activity as estimated by biochemical markers.

    ActiTest FibroTest HCV

  107. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Match 65

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  108. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 65

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  109. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 64

    …combinations of simple serum biochemical markers (the super combination being FibroMAX (BioPredictive…

    ActiTest AshTest FibroTest NashTest +7

  110. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 64

    ### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…

    ActiTest FibroTest HCV

  111. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 64

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  112. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 63

    …This study aimed to prospectively assess the potential of noninvasive markers for…

    FibroTest Other

  113. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

    Boursier J et al. · Hepatology · 2012 Match 63

    ### Unlabelled The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm…

    FibroTest HCV

  114. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 63

    FibroTest HBV

  115. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

    Akuta N et al. · J Gastroenterol · 2018 Match 62

    ### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…

    FibroTest HCV

  116. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012 Match 62

    ### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…

    FibroTest HCV

  117. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 62

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  118. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 61

    ### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…

    FibroTest HCV

  119. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 61

    ### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…

    FibroTest HCV

  120. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 61

    ### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…

    AshTest Alcohol

  121. Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

    Calès P et al. · Clin Biochem · 2010 Match 60

    …or blood markers. ### Results The bootstrap method validated the markers of the…

    FibroTest HCV

  122. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 60

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  123. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 60

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  124. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 59

    ### Purpose To compare the diagnostic performance of acoustic radiation force impulse (ARFI…

    FibroTest Alcohol HBV HCV +2

  125. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 59

    ### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…

    FibroTest Metabolic

  126. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Match 59

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  127. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010 Match 58

    ### Background & Aims The diagnostic accuracy of non-invasive liver fibrosis tests that…

    FibroTest HBV HCV HIV

  128. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 58

    ActiTest FibroTest NashTest-2 Metabolic

  129. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 58

    …Currently, although several non-invasive fibrosis markers have been suggested as alternatives…

    FibroTest Alcohol

  130. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 57

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  131. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 57

    FibroTest Alcohol

  132. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 57

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  133. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 56

    ### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…

    FibroTest Alcohol HBV HCV +1

  134. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 56

    …on direct and/or indirect markers) such as APRI, FIB4, FibroTest, FibroSpect…

    FibroTest HBV HCV HIV

  135. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 56

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  136. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

    Poynard T et al. · Comp Hepatol · 2004 Match 55

    …In 2001, FibroTest ActiTest (FT-AT), a panel of biochemical markers, was…

    ActiTest FibroTest HCV

  137. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 55

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  138. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 55

    ### Background Previous research has shown variation in the effects of patient factors…

    FibroTest HCV

  139. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 54

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  140. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 54

    ### Background Urea cycle disorders (UCDs) are among the most common inborn errors…

    ActiTest FibroTest Other

  141. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 54

    …diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral…

    FibroTest Metabolic

  142. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 53

    Chronic hepatitis B virus (HBV) infection is a major cause of liver…

    FibroTest HBV

  143. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 53

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  144. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 53

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

  145. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 52

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  146. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 52

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  147. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 52

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  148. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 51

    Chronic hepatitis B (CHB) infection is a major public health problem associated…

    FibroTest HBV

  149. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.